Skip to main
CLDX
CLDX logo

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics Inc. has demonstrated its financial resilience with a robust cash position of $725.3 million, which management anticipates will support operations through 2027. The ongoing clinical trials for its lead product, barzolvolimab, have shown promising results in improving quality of life for patients with chronic spontaneous urticaria, reinforcing the product's potential across multiple indications. With data indicating sustained improvement in disease control and quality of life metrics, particularly regarding chronic urticaria, the company positions itself favorably within the biopharmaceutical industry.

Bears say

Celldex Therapeutics faces significant risks that could adversely affect its stock outlook, primarily stemming from the potential for failed or inconclusive clinical trials, which could hinder the advancement of its drug pipeline. Additionally, the company may struggle to secure sufficient funding necessary for continued development and commercialization of its therapeutic products. The existing data indicates a high unmet need, with two-thirds of patients not achieving complete control of their disease, which could impact the commercial viability of its treatments.

Celldex Therapeutics (CLDX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 17 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.